<DOC>
	<DOC>NCT00352339</DOC>
	<brief_summary>Switching from Risperidone to Aripiprazole in early stage of pharmacotherapy will demonstrate the same efficacy as compared to risperidone continuation treatment in the treatment of schizophrenia.</brief_summary>
	<brief_title>The New Strategy for Pharmacological Treatment in People With Schizophrenia</brief_title>
	<detailed_description>It has been thought that D2 Blocking agent is necessary in acute as well as maintenance phase of pharmacological treatment of patients with schizophrenia. However, this classical strategy produces long term adverse events of drug such as TD, osteoporosis and some metabolic syndrome. To overcome these adverse events, new strategy for pharmacological treatment is needed.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Schizophrenia, DSMIV Acute phase Refractory Schizophrenia Substance Abuse High risk for suicide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Switching</keyword>
	<keyword>Early stage</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Aripirazole</keyword>
</DOC>